Search results for "From Annals of Internal Medicine"
Canagliflozin safe, tolerable in kids, adolescents, manufacturer study finds
A phase 3 trial found significantly greater reductions in HbA1c levels in children and adolescents 10 years of age and older who were randomized to canagliflozin versus placebo.
https://diabetes.acponline.org/archives/2025/08/08/7.htm
8 Aug 2025
Dementia risk similar with GLP-1 receptor agonists, DPP-4 inhibitors
A target trial emulation that matched Medicare patients who started glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors did not find a significant difference in their dementia risk.
https://diabetes.acponline.org/archives/2025/08/08/6.htm
8 Aug 2025
Annals On Call: Expenditures after bariatric surgery
Annals On Call is a podcast focusing on a clinically influential article published in Annals of Internal Medicine. A recent episode discussed the health expenditures of patients with diabetes who undergo bariatric surgery.
https://diabetes.acponline.org/archives/2025/05/09/7.htm
9 May 2025
Only 4 of 14 diabetes performance measures adequate, ACP position paper says
The College's Performance Measurement Committee recently reviewed 14 current performance measures for diabetes that are relevant to internal medicine.
https://diabetes.acponline.org/archives/2025/05/09/6.htm
9 May 2025
ED visits for semaglutide adverse events rare, study suggests
The majority of ED visits related to taking semaglutide were attributed to gastrointestinal complications and hypoglycemia.
https://diabetes.acponline.org/archives/2025/04/11/6.htm
11 Apr 2025
In the Clinic, Ideas and Opinions address diabetes
A recent In the Clinic reviewed hyperglycemia in hospitalized patients, and an opinion article discussed misuse of race in interpretation of HbA1c levels.
https://diabetes.acponline.org/archives/2024/12/13/8.htm
13 Dec 2024
Medicare coverage of semaglutide would be costly
Covering semaglutide for patients who are overweight and have cardiovascular disease could cost Medicare an additional $34 to $145 billion annually, researchers estimated.
https://diabetes.acponline.org/archives/2024/09/13/7.htm
13 Sep 2024
Little difference in dementia risk with SGLT-2s vs. dulaglutide
Older patients with type 2 diabetes starting sodium-glucose cotransporter-2 (SGLT-2) inhibitors had an estimated difference of less than a percentage point in five-year risk of clinical onset of dementia compared with those starting the glucagon-like peptide-1 receptor agonist dulaglutide, a South Korean study found.
https://diabetes.acponline.org/archives/2024/09/13/6.htm
13 Sep 2024
Use of GLP-1 receptor agonists rose steeply in past decade, study finds
A million U.S. patients, mostly women, started taking glucagon-like peptide-1 (GLP-1) receptor agonists between 2011 and 2023, according to an analysis of medical records across the country.
https://diabetes.acponline.org/archives/2024/08/09/6.htm
9 Aug 2024
Latest Beyond the Guidelines, In the Clinic target diabetes
An endocrinologist and a nephrologist discuss appropriate care for type 2 diabetes and chronic kidney disease, and the evidence supporting type 2 diabetes prevention and treatment are reviewed.
https://diabetes.acponline.org/archives/2024/06/14/6.htm
14 Jun 2024
SGLT-2 inhibitors associated with improved outcomes in stage 5 CKD patients
Patients with type 2 diabetes and stage 5 chronic kidney disease (CKD) had lower risk of progressing to dialysis or having a cardiovascular event if they took sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a study found.
https://diabetes.acponline.org/archives/2024/05/10/6.htm
10 May 2024
State caps on insulin costs for commercially insured didn't increase insulin use
Limits on out-of-pocket costs did lower patients' insulin expenses, but the effect was mostly limited to those with health savings accounts, a pre-post comparison among U.S. states found.
https://diabetes.acponline.org/archives/2024/04/12/6.htm
12 Apr 2024
Annals On Call: Type 1 diabetes
Annals On Call is a podcast focusing on a clinically influential article published in Annals of Internal Medicine. A recent episode discussed the age at which U.S. adults with type 1 diabetes are being diagnosed.
https://diabetes.acponline.org/archives/2023/12/08/8.htm
8 Dec 2023
Diabetes more common in low-income middle-aged people, rising among higher-income group
Between 1999 and 2020, rates of diabetes and obesity held steady in lower-income middle-aged adults in the U.S., while these risk factors rose among the higher-income middle-aged, from 7.8% to 14.9% and 33.0% to 44.0%, respectively.
https://diabetes.acponline.org/archives/2023/12/08/7.htm
8 Dec 2023
Finerenone works by quickly lowering albuminuria, analysis finds
Reductions in the urine albumin-to-creatinine ratio within four months were responsible for 84% of the treatment effect of finerenone on kidney outcomes and 37% of that on cardiovascular outcomes, according to an industry-funded four-year analysis of trials in patients with chronic kidney disease and type 2 diabetes.
https://diabetes.acponline.org/archives/2023/12/08/6.htm
8 Dec 2023
Weekly insulin icodec superior to daily insulin analogues in latest manufacturer trial
Patients with type 2 diabetes who used weekly insulin icodec and a dosing app had greater reductions in HbA1c levels than similar patients randomized to start a daily insulin analogue with a traditional dosing strategy.
https://diabetes.acponline.org/archives/2023/10/13/6.htm
13 Oct 2023
Insulin costs, diabetes and testosterone
An Ideas and Opinions piece explained some of the factors behind insulin prices, and a meta-analysis looked at testosterone levels in men with diabetes.
https://diabetes.acponline.org/archives/2023/09/08/6.htm
8 Sep 2023
Crowdfunding campaigns often focus on overall cost of diabetes, rarely mention insulin
A quarter of fundraisers for patients with diabetes reported that the patient had insurance, and many mentioned noncovered costs such as lost wages, healthy food, and diabetic alert dogs.
https://diabetes.acponline.org/archives/2023/07/14/6.htm
14 Jul 2023
ACP Journal Club: SGLT-2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
The results of this meta-analysis of sodium-glucose cotransporter-2 (SGLT-2) inhibitors highlight the opportunity for internists, nephrologists, endocrinologists, and cardiologists to collaborate to expand use of the drug class, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/03/10/7.htm
10 Mar 2023
Annals On Call: First-line drug therapy for type 2 diabetes
Annals On Call is a podcast focusing on a clinically influential article published in Annals of Internal Medicine. A recent episode covered a study of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists as first-line therapy.
https://diabetes.acponline.org/archives/2023/03/10/6.htm
10 Mar 2023